Abstract: The present disclosure provides a novel conjugate or a pharmaceutically acceptable salt thereof, wherein the conjugate has an active pharmaceutical moiety or a prodrug thereof, a targeting module and a linker therebetween. The conjugate or a pharmaceutically acceptable salt thereof is useful for treating a disease, recurrence or progression in a subject or increasing the likelihood of survival over a relevant period in a subject diagnosed with a disease.

Abstract: A method of preparing a triterpenoid compound of formula (I): including a step of converting a compound of formula (II) into the compound of formula (I), wherein R1 and R2 independently represent hydrogen or a protecting group selected from the group consisting of C1-C8 alkyl, allyl, C2-C8 alkenyl, C2-C8 alkynyl, (C6-C12)aryl(C1-C8)alkyl, tri(C1-C8)alkylsilyl, di(C1-C8)alkyl(C6-C12)arylsilyl, di(C6-C12)aryl(C1-C8)alkylsilyl ,tri(C6-C12)arylsilyl, —C(O)R7, and —C(O)OR8, and each of which is substituted with from 0 to 4 substituents independently selected from the group consisting of hydroxy, cyano, halo, halo(C1-C6)alkyl, halo(C1-C6)alkyloxy, (C1-C6)alkylthio, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl and C1-C6 alkoxy, wherein R7 and R8 are independently C1-C8 alkyl or C6-C12 aryl.

Abstract: The present invention is directed to novel chemical compounds in which a lipophilic moiety such as a lipid, fatty acid, polyethylene glycol or terpene is covalently attached to a non-acylated or desacylated triterpene saponin via a carboxyl group present on the 3-O-glucuronic acid of the triterpene saponin. The attachment of a lipophile moiety to the 3-O-glucuronic acid of a saponin such as Quillaja desacylsaponin, lucyoside P, or saponin from Gypsophila, Saponaria and Acanthophyllum enhances their adjuvant effects on humoral and cell mediated immunity. Additionally, the attachment of a lipophile moiety to the 3-O-glucuronic acid residue of non- or des-acylsaponin yields a saponin analog that is easier to purify, less toxic, chemically more stable, and possesses equal or better adjuvant properties than the original saponin.

Abstract: Methods for synthesis and preparation of alpha-glycosphingolipids are provided. Methods for synthesis of ?-galactosyl ceramide, and pharmaceutically active analogs and variants thereof are provided. Novel alpha-glycosphingolipids are provided, wherein the compounds are immunogenic compounds which serve as ligands for NKT (natural killer T) cells.

Abstract: Methods for synthesis and preparation of alpha-glycosphingolipids are provided. Methods for synthesis of ?-galactosyl ceramide, and pharmaceutically active analogs and variants thereof are provided. Novel alpha-glycosphingolipids are provided, wherein the compounds are immunogenic compounds which serve as ligands for NKT (natural killer T) cells.

Abstract: Methods for synthesis and preparation of alpha-glycosphingolipids are provided. Methods for synthesis of ?-galactosyl ceramide, and pharmaceutically active analogs and variants thereof are provided. Novel alpha-glycosphingolipids are provided, wherein the compounds are immunogenic compounds which serve as ligands for NKT (natural killer T) cells.

Abstract: A method, system and device to identify, study and/or mimic carbohydrate-protein interactions on cell surfaces and in solution measured by a glycan microarray. In some instances the method, system and device uses very small quantities of carbohydrate as low as attomol. In some instances the system, method and device is high-throughput. The small quantity senstivity may allow for close placement of carbohydrate array members wherein due to close proximity multivalent interactions with proteins may be identified.

Abstract: A method, system and device to identify, study and/or mimic carbohydrate-protein interactions on cell surfaces and in solution measured by a glycan microarray. In some instances the method, system and device uses very small quantities of carbohydrate as low as attomol. In some instances the system, method and device is high-throughput. The small quantity sensitivity may allow for close placement of carbohydrate array members wherein due to close proximity multivalent interactions with proteins may be identified.

Abstract: The protein CD1d binds self and foreign glycolipids for presentation to CD1-restricted T cells by means of TCR recognition, and activates TH1 and TH2 chemokines release. Accordingly, a variety of glycolipid ligands were attached to a microarray surface and their binding with CD1d investigated. An ?-galactosyl ceramide (?-GalCer) bearing a carbamate group at the 6?-OH position was tethered to the surface and the dissociation constant with CD1d determined. Competition assays were used to determine the dissociation constants (Ki) of the new and intact glycolipids. The para-fluoroheptaphenyl-modified ?-GalCer was found to bind most strongly with CD1d (Ki 0.14 ?M), two orders of magnitude stronger than ?-GalCer and more than three times more selective for IFN-? release.

Abstract: Novel 5-membered iminocyclitol derivatives were found to be a potent and selective inhibitors of the glycoprotein processing ?- and ?-glucosidase which were further found to be active antiviral agents against Japanese encephalitis virus, dengue virus serotype 2 (DEN-2), human SARS coronavirus and human ?-hexosaminidase, a new target for development of osteoarthritis therapeutics.

Abstract: Methods for synthesis and preparation of alpha-glycosphingolipids are provided. Methods for synthesis of ?-galactosyl ceramide, and pharmaceutically active analogs and variants thereof are provided. Novel alpha-glycosphingolipids are provided, wherein the compounds are immunogenic compounds which serve as ligands for NKT (natural killer T) cells.

Abstract: Novel 5-membered iminocyclitol derivatives were found to be a potent and selective inhibitors of the glycoprotein processing ?- and ?-glucosidase which were further found to be active antiviral agents against Japanese encephalitis virus, dengue virus serotype 2 (DEN-2), human SARS coronavirus and human ?-hexosaminidase, a new target for development of osteoarthritis therapeutics.

Abstract: Novel 5-membered iminocyclitol derivatives were found to be a potent and selective inhibitors of the glycoprotein processing ?- and ?-glucosidase which were further found to be active antiviral agents against Japanese encephalitis virus, dengue virus serotype 2 (DEN-2), human SARS coronavirus and human ?-hexosaminidase, a new target for development of osteoarthritis therapeutics.

Abstract: Novel 5-membered iminocyclitol derivatives were found to be a potent and selective inhibitors of the glycoprotein processing ?- and ?-glucosidase which were further found to be active antiviral agents against Japanese encephalitis virus, dengue virus serotype 2 (DEN-2), human SARS coronavirus and human ?-hexosaminidase, a new target for development of osteoarthritis therapeutics.

Abstract: A method, system and device to identify, study and/or mimic carbohydrate-protein interactions on cell surfaces and in solution measured by a glycan microarray. In some instances the method, system and device uses very small quantities of carbohydrate as low as attomol. In some instances the system, method and device is high-throughput. The small quantity sensitivity may allow for close placement of carbohydrate array members wherein due to close proximity multivalent interactions with proteins may be identified.

Abstract: The protein CD1d binds self and foreign glycolipids for presentation to CD1-restricted T cells by means of TCR recognition, and activates TH1 and TH2 chemokines release. Accordingly, a variety of glycolipid ligands were attached to a microarray surface and their binding with CD1d investigated. An ?-galactosyl ceramide (?-GalCer) bearing a carbamate group at the 6?-OH position was tethered to the surface and the dissociation constant with CD1d determined. Competition assays were used to determine the dissociation constants (Ki) of the new and intact glycolipids. The para-fluoroheptaphenyl-modified ?-GalCer was found to bind most strongly with CD1d (Ki 0.14 ?M), two orders of magnitude stronger than ?-GalCer and more than three times more selective for IFN-? release.

Abstract: A conserved cluster of oligomannose glycans on gp120 has been identified as the epitope recognized by the broadly HIV-1-neutralizing monoclonal antibody 2G12. Oligomannose glycans are also the ligands for DC-SIGN, a C-type lectin found on the surface of dendritic cells. Multivalency is fundamental for carbohydrate-protein interactions, and mimicking of the high glycan density on the virus surface has become essential for designing carbohydrate-based HIV vaccines and antiviral agents. Synthesis of oligomannose dendrons, which display multivalent oligomannoses in high density, and characterize their interaction with 2G12 and DC-SIGN by a glycan microarray binding assay is disclosed. These glycodendrons inhibit the binding of gp120 to 2G12 and recombinant dimeric DC-SIGN with IC50 in the nanomolar range. A second-generation Man9 dendron was identified as a potential immunogen for HIV vaccine development and as a potential antiviral agent.